- Conditions
- Chronic Kidney Disease
- Interventions
- Group 2: Dasatinib, Group 2: Quercetin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 73
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Advanced Breast Cancer
- Interventions
- Dasatinib, Fulvestrant
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 28
- States / cities
- Sedona, Arizona • Tucson, Arizona • Hudson, Florida + 22 more
- Conditions
- Scleroderma
- Interventions
- dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Farmington, Connecticut + 10 more
- Conditions
- Advanced Breast Cancer
- Interventions
- Dasatinib, Capecitabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • New York, New York + 1 more
- Conditions
- Relapsed, Refractory or Plateau Phase Multiple Myeloma
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Interventions
- Palbociclib, Dexamethasone, Bortezomib, Doxorubicin
- Drug
- Lead sponsor
- Tanja Andrea Gruber
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pharmacokinetic Study in Healthy Participants
- Interventions
- Dasatinib as tablets, Dasatinib as liquid, Dasatinib as dispersed tablets
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy
- Interventions
- Dasatinib + Omeprazole
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Hamilton, New Jersey
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Dasatinib and Rituximab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Dasatinib, Combination of Bendamustine + Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- New Hyde Park, New York • Columbus, Ohio • Nashville, Tennessee
- Conditions
- Prostate Cancer
- Interventions
- dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- Dasatinib, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Atlanta, Georgia
- Conditions
- Chronic Phase Chronic Myeloid Leukemia
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Anaheim, California • Southington, Connecticut • Baltimore, Maryland + 2 more
- Conditions
- Breast Cancer
- Interventions
- Exemestane + Dasatinib, Exemestane + Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Fountain Valley, California • Riverside, California • Philadelphia, Pennsylvania + 1 more
- Conditions
- Leukemia
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 11 more
- Conditions
- Breast Cancer, Metastasis
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 5
- States / cities
- San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- RO7283420, Tocilizumab, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Sacramento, California • Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
- Drug · Procedure
- Lead sponsor
- Noah Hahn, M.D.
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Gainesville, Florida • Chicago, Illinois + 3 more
- Conditions
- HIV, Frailty, Prefrail, Aging Problems
- Interventions
- Dasatinib, Quercetin, Placebo - Dasatinib, Placebo - Quercetin
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 24
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 18 more
- Conditions
- Stem Cell Transplant
- Interventions
- Standard of Care - Observation Only, Group 2: Quercetin, Group 2: Dasatinib
- Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Dasatinib, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
- Conditions
- Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
- Interventions
- dasatinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Columbus, Ohio • Houston, Texas
- Conditions
- Frailty, Childhood Cancer
- Interventions
- Dasatinib plus Quercetin, Fisetin
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Multiple Myeloma
- Interventions
- Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg, Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg, Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona